相关实验视频

Updated: Jun 21, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

微RNAmiRNA-206在乳腺癌发病过程中的潜在功能:机制方面和临床影响

Esmaeel Babaeenezhad¹, Zohreh Abdolvahabi², Sahar Asgharzadeh²

¹Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran; Department of Biochemistry and Genetics, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

Pathology, research and practice

|July 13, 2024

概括

微RNA-206 (miRNA-206) 在乳腺癌 (BC) 中扮演着双重角色,同时作为瘤基因和瘤抑制剂. 它的表达水平为诊断和治疗BC提供了潜在的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一种遗传学.

背景情况:

乳腺癌 (BC) 是一个重要的全球健康问题.
miRNA-206因其参与BC发育和进展而得到越来越多的认可.
改变的miRNA-206表达与BC的关键临床病理特征相关.

研究的目的:

审查和综合有关乳腺癌中miRNA-206功能的当前知识.
探索miRNA-206.6的双重致癌和瘤抑制作用.
评估miRNA-206在BC的诊断,预后和治疗潜力.

主要方法:

文献综述和对乳腺癌中miRNA-206现有研究的综合.
对研究miRNA-206表达,目标和临床相关性的研究进行分析.
讨论miRNA-206.6的上游调节剂和下游影响.

主要成果:

miRNA-206表现出上下文依赖的功能,影响促进癌症和抑制癌症的途径.
miRNA-206的表达水平与淋巴结转移,瘤大小,阶段,化疗耐药性和患者存活率有关.
已识别的上游监管器和下游目标为miRNA-206的监管网络提供了洞察力.

结论:

miRNA-206具有作为乳腺癌诊断和预后的生物标志物的巨大潜力.
了解miRNA-206的复杂作用可能为针对乳腺癌的新型治疗策略铺平道路.
需要进一步的研究来充分阐明miRNA-206的机制和临床应用.

关键词:

乳腺癌是什么? 乳腺癌是什么这就是米RNA-206的原因.在瘤基因上,我们发现了癌症.预测预后预测预测瘤抑制剂是一种瘤抑制剂.上游调节器上游调节器

更多相关视频

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...